EMA Authorised: Krazati (adagrasib) — Bristol-Myers Squibb Pharma EEIG

View source ↗

Summary

Authorised approval of Krazati (adagrasib) for non-small cell lung carcinoma by EMA, issued to Bristol-Myers Squibb Pharma EEIG with conditional approval.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Carcinoma Non-small-cell Lung

Drugs mentioned

• KRAZATI (adagrasib)

Snippet

Status: Authorised. Therapeutic area: Carcinoma, Non-Small-Cell Lung. MAH: Bristol-Myers Squibb Pharma EEIG. Decision date: 20/08/2026. Conditional approval